Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8085)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Sep 26, 2014 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Stem Cells
ISSN
1948-0210
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Haygood CLW, Arend RC, Straughn JM, Buchsbaum DJ. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells 2014; 6(4): 441-447 [PMID: 25258665 DOI: 10.4252/wjsc.v6.i4.441] |
|---|---|
| URL: | https://www.wjgnet.com/1948-0210/full/v6/i4/441.htm |
| Number | Citing Articles |
| 1 |
Sahitya K. Denduluri, Olumuyiwa Idowu, Zhongliang Wang, Zhan Liao, Zhengjian Yan, Maryam K. Mohammed, Jixing Ye, Qiang Wei, Jing Wang, Lianggong Zhao, Hue H. Luu. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes & Diseases 2015; 2(1): 13 doi: 10.1016/j.gendis.2014.10.004
|
| 2 |
Chinnadurai Mani, Kaushlendra Tripathi, Tasmin R. Omy, Mark Reedy, Upender Manne, Komaraiah Palle. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2022; 1868(2): 166300 doi: 10.1016/j.bbadis.2021.166300
|
| 3 |
Alessandra Ardizzoia, Andrea Jemma, Serena Redaelli, Marco Silva, Angela Bentivegna, Marialuisa Lavitrano, Donatella Conconi. AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer. International Journal of Molecular Sciences 2023; 24(14): 11455 doi: 10.3390/ijms241411455
|
| 4 |
Asunción Espinosa-Sánchez, Elisa Suárez-Martínez, Laura Sánchez-Díaz, Amancio Carnero. Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.01533
|
| 5 |
Lei Zhao, Zhi‐gang Wang, Ping Zhang, Xiu‐feng Yu, Xiao‐jie Su. Poly r(C) Binding Protein 1 Regulates Posttranscriptional Expression of the Ubiquitin Ligase TRIM56 in Ovarian Cancer. IUBMB Life 2019; 71(2): 177 doi: 10.1002/iub.1948
|
| 6 |
Ivan Lučić, Matea Kurtović, Monika Mlinarić, Nikolina Piteša, Ana Čipak Čipak Gašparović, Maja Sabol, Lidija Milković. Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches. International Journal of Molecular Sciences 2023; 24(13): 10683 doi: 10.3390/ijms241310683
|
| 7 |
Nicole Anderle, André Koch, Berthold Gierke, Anna-Lena Keller, Annette Staebler, Andreas Hartkopf, Sara Y. Brucker, Michael Pawlak, Katja Schenke-Layland, Christian Schmees. A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer. Cancers 2022; 14(12): 2895 doi: 10.3390/cancers14122895
|
| 8 |
Shan Qin, Yanfang Li, Xuexia Cao, Jiexian Du, Xianghua Huang. NANOG regulates epithelial–mesenchymal transition and chemoresistance in ovarian cancer. Bioscience Reports 2017; 37(1) doi: 10.1042/BSR20160247
|
| 9 |
Heejin Lee, Oh-Bin Kwon, Jae-Eon Lee, Yong-Hyun Jeon, Dong-Seok Lee, Sang-Hyun Min, Jun-Woo Kim. Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells. Cells 2021; 10(4): 918 doi: 10.3390/cells10040918
|
| 10 |
Yingying Wang, Juan Wang, Jianxin Zhong, Yan Deng, Qinghua Xi, Song He, Shuyun Yang, Lifei Jiang, Menghui Huang, Chunhui Tang, Rong Liu. Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer. Medical Oncology 2015; 32(1) doi: 10.1007/s12032-014-0379-8
|
| 11 |
Carlotta Sabini, Flavia Sorbi, Paula Cunnea, Christina Fotopoulou. Ovarian cancer stem cells: ready for prime time?. Archives of Gynecology and Obstetrics 2020; 301(4): 895 doi: 10.1007/s00404-020-05510-9
|
| 12 |
Arkene Levy, Carolina Leynes, Mirza Baig, Sue Anne Chew. The Application of Biomaterials in the Treatment of Platinum‐Resistant Ovarian Cancer. ChemMedChem 2019; 14(21): 1810 doi: 10.1002/cmdc.201900450
|
| 13 |
Marbelis Francisco Fernandez, Cyndia Charfi, Janet Piloto-Ferrer, Maria Lidia González, Sylvie Lamy, Borhane Annabi. Targeting Ovarian Cancer Cell Cytotoxic Drug Resistance Phenotype with Xanthium strumarium L. Extract. Evidence-Based Complementary and Alternative Medicine 2019; 2019: 1 doi: 10.1155/2019/6073019
|
| 14 |
Amoura Abou-ElNaga, Ghada Mutawa, Ibrahim El-Sherbiny, Hassan Abd-ElGhaffar, Ahmed Allam, Jamaan Ajarem, Shaker Mousa. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice. International Journal of Molecular Sciences 2017; 18(4): 813 doi: 10.3390/ijms18040813
|
| 15 |
Jing Ma, Joseph Salamoun, Peter Wipf, Robert Edwards, Bennett Van Houten, Wei Qian. Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 2018; 9(5): 6042 doi: 10.18632/oncotarget.23679
|
| 16 |
Sandra Muñoz-Galván, Blanca Felipe-Abrio, Miguel García-Carrasco, Julia Domínguez-Piñol, Elisa Suarez-Martinez, Eva M. Verdugo-Sivianes, Asunción Espinosa-Sánchez, Lola E. Navas, Daniel Otero-Albiol, Juan J. Marin, Manuel P. Jiménez-García, Jose M. García-Heredia, Adoración G. Quiroga, Purificacion Estevez-Garcia, Amancio Carnero. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1245-5
|
| 17 |
Rebecca C. Arend, Angelina I. Londoño-Joshi, Abhishek Gangrade, Ashwini A. Katre, Chandrika Kurpad, Yonghe Li, Rajeev S. Samant, Pui-Kai Li, Charles N. Landen, Eddy S. Yang, Bertha Hidalgo, Ronald D. Alvarez, John Michael Straughn, Andres Forero, Donald J. Buchsbaum. Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. Oncotarget 2016; 7(52): 86803 doi: 10.18632/oncotarget.13466
|
| 18 |
Dallas A Vanorny, Kelly E Mayo. The role of Notch signaling in the mammalian ovary. Reproduction 2017; 153(6): R187 doi: 10.1530/REP-16-0689
|
| 19 |
SHIHONG MA, WENHUA TAN, BOTAO DU, WEI LIU, WEIJIA LI, DEHONG CHE, GUANGMEI ZHANG. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Molecular Medicine Reports 2016; 13(4): 3342 doi: 10.3892/mmr.2016.4897
|
| 20 |
Eun Jung Choi, Eun Jin Seo, Dae Kyoung Kim, Su In Lee, Yang Woo Kwon, Il Ho Jang, Ki-Hyung Kim, Dong-Soo Suh, Jae Ho Kim. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget 2016; 7(3): 3506 doi: 10.18632/oncotarget.6510
|
| 21 |
Chenglong Wang, Fanchen Wang, Jinguo Zhang, Lingshan Liu, Guoxiong Xu, Hongjing Dou. Fluorescent Polysaccharide Nanogels for the Detection of Tumor Heterogeneity in Drug‐Surviving Cancer Cells. Advanced Biosystems 2020; 4(2) doi: 10.1002/adbi.201900213
|
| 22 |
Ping Chen, Ruochen Dong, Qi Chen. Extracts of the Medicinal Plants Pao Pereira and Rauwolfia vomitoria Inhibit Ovarian Cancer Stem Cells In Vitro. Integrative Cancer Therapies 2022; 21: 153473542211230 doi: 10.1177/15347354221123019
|
| 23 |
Anshuly Tiwari, Siddharth J. Modi, Satish Y. Gabhe, Vithal M. Kulkarni. Evaluation of piperine against cancer stem cells (CSCs) of hepatocellular carcinoma: Insights into epithelial-mesenchymal transition (EMT). Bioorganic Chemistry 2021; 110: 104776 doi: 10.1016/j.bioorg.2021.104776
|
| 24 |
Soozana Puvanenthiran, Sharadah Essapen, Alan M. Seddon, Helmout Modjtahedi. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. International Journal of Oncology 2016; 49(5): 1825 doi: 10.3892/ijo.2016.3678
|
| 25 |
Pratibha S. Binder, Jaime Prat, David G. Mutch. Molecular staging of gynecological cancer: What is the future?. Best Practice & Research Clinical Obstetrics & Gynaecology 2015; 29(6): 776 doi: 10.1016/j.bpobgyn.2015.01.008
|
| 26 |
Pratibha S. Binder, Jaime Prat, David G. Mutch. The future role of molecular staging in gynecologic cancer. International Journal of Gynecology & Obstetrics 2015; 131(S2) doi: 10.1016/j.ijgo.2015.06.009
|
| 27 |
Urmila Sehrawat, Ruchika Pokhriyal, Ashish Kumar Gupta, Roopa Hariprasad, Mohd Imran Khan, Divya Gupta, Jasmine Naru, Sundararajan Baskar Singh, Ashok Kumar Mohanty, Perumal Vanamail, Lalit Kumar, Sunesh Kumar, Gururao Hariprasad. Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel. Biomarkers in Cancer 2016; 8: BIC.S35775 doi: 10.4137/BIC.S35775
|
| 28 |
Siddharth J. Modi, Vithal M. Kulkarni. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma. European Journal of Medicinal Chemistry 2020; 207: 112851 doi: 10.1016/j.ejmech.2020.112851
|
| 29 |
Gonzalo H. Giornelli. Management of relapsed ovarian cancer: a review. SpringerPlus 2016; 5(1) doi: 10.1186/s40064-016-2660-0
|
| 30 |
D. M. Janzen, E. Tiourin, J. A. Salehi, D. Y. Paik, J. Lu, M. Pellegrini, S. Memarzadeh. RETRACTED ARTICLE: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nature Communications 2015; 6(1) doi: 10.1038/ncomms8956
|
| 31 |
Kevin Brasseur, Nicolas Gévry, Eric Asselin. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017; 8(3): 4008 doi: 10.18632/oncotarget.14021
|
| 32 |
Alberta Bergamo, Gianni Sava. Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chemical Society Reviews 2015; 44(24): 8818 doi: 10.1039/C5CS00134J
|
| 33 |
Lei Zhao, Ping Zhang, Xiao‐jie Su, Bing Zhang. The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin. Journal of Cellular Physiology 2018; 233(3): 2420 doi: 10.1002/jcp.26114
|
| 34 |
Benjamin B. Kasten, Soldano Ferrone, Kurt R. Zinn, Donald J. Buchsbaum. B7-H3-targeted Radioimmunotherapy of Human Cancer. Current Medicinal Chemistry 2020; 27(24): 4016 doi: 10.2174/0929867326666190228120908
|
| 35 |
Kalaivani Kalamohan, Paramasamy Gunasekaran, Syed Ibrahim. Gene coexpression network analysis of multiple cancers discovers the varying stem cell features between gastric and breast cancer. Meta Gene 2019; 21: 100576 doi: 10.1016/j.mgene.2019.100576
|
| 36 |
Alaa M. Khalifa, Manal A. Elsheikh, Amr M. Khalifa, Yosra S.R. Elnaggar. Current strategies for different paclitaxel-loaded Nano-delivery Systems towards therapeutic applications for ovarian carcinoma: A review article. Journal of Controlled Release 2019; : 125 doi: 10.1016/j.jconrel.2019.08.034
|
| 37 |
Tianqi Xu, Anzhelika Vorobyeva, Alexey Schulga, Elena Konovalova, Olga Vorontsova, Haozhong Ding, Torbjörn Gräslund, Liubov A. Tashireva, Anna Orlova, Vladimir Tolmachev, Sergey M. Deyev. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. Cancers 2021; 13(16): 3939 doi: 10.3390/cancers13163939
|
| 38 |
Vahideh Keyvani, Espanta Riahi, Meysam Yousefi, Seyed-Alireza Esmaeili, Rana Shafabakhsh, Amin Moradi Hasan-Abad, Maryam Mahjoubin-Tehran, Michael R. Hamblin, Samaneh Mollazadeh, Hamed Mirzaei. Gynecologic Cancer, Cancer Stem Cells, and Possible Targeted Therapies. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.823572
|
| 39 |
Eun Jin Seo, Yang Woo Kwon, Il Ho Jang, Dae Kyoung Kim, Soo In Lee, Eun Jung Choi, Ki-Hyung Kim, Dong-Soo Suh, Jeong Hee Lee, Kyung Un Choi, Jae Won Lee, Hyuck Jun Mok, Kwang Pyo Kim, Hirotaka Matsumoto, Junken Aoki, Jae Ho Kim. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism. Stem Cells 2016; 34(3): 551 doi: 10.1002/stem.2279
|
| 40 |
Vahideh Keyvani, Moein Farshchian, Seyed-Alireza Esmaeili, Hadi Yari, Meysam Moghbeli, Seyed-Reza Kazemi Nezhad, Mohammad Reza Abbaszadegan. Ovarian cancer stem cells and targeted therapy. Journal of Ovarian Research 2019; 12(1) doi: 10.1186/s13048-019-0588-z
|
| 41 |
Andrzej Nowicki, Magdalena Kulus, Maria Wieczorkiewicz, Wojciech Pieńkowski, Katarzyna Stefańska, Paulina Skupin-Mrugalska, Rut Bryl, Paul Mozdziak, Bartosz Kempisty, Hanna Piotrowska-Kempisty. Ovarian Cancer and Cancer Stem Cells—Cellular and Molecular Characteristics, Signaling Pathways, and Usefulness as a Diagnostic Tool in Medicine and Oncology. Cancers 2021; 13(16): 4178 doi: 10.3390/cancers13164178
|
| 42 |
Iyer Mahalaxmi, Subramaniam Mohana Devi, Jayaramayya Kaavya, Narayanasamy Arul, Vellingiri Balachandar, Kumaran Sivanandan Santhy. New insight into NANOG: A novel therapeutic target for ovarian cancer (OC). European Journal of Pharmacology 2019; 852: 51 doi: 10.1016/j.ejphar.2019.03.003
|